计算溶液所需的质量、体积或浓度。
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
E128064-5mg |
5mg |
现货 ![]() |
| |
E128064-25mg |
25mg |
现货 ![]() |
| |
E128064-100mg |
100mg |
现货 ![]() |
|
别名 | 依瓦塞特拉匹布 (LY2484595) |
---|---|
英文别名 | Trans-4-(((5S)-5-(((3,5-bis(trifluoromethyl)phenyl)methyl)(2-methyl-2H-tetrazol-5- yl)amino)-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzazepin-1-yl)methyl) cyclohexanecarboxylic acid | Q553129 | 2-pyridine-carboxaldehyde | 4-trans-(((S)-5-((3,5-Bis(trifluorom |
规格或纯度 | Moligand™, ≥98% |
英文名称 | Evacetrapib (LY2484595) |
生化机理 | Evacetrapib (LY2484595) 可抑制人血浆 CETP 蛋白,IC50 为 26 nM。Evacetrapib (LY2484595)(< 10 μM)不会诱导 H295R 细胞合成醛固酮或皮质醇。Evacetrapib (LY2484595)(30 mg/kg,口服)在人类载脂蛋白AI和CETP双转基因小鼠中,分别在服药后4小时、8小时和24小时抑制98.4%、98.6%和18.4%的CETP活性。口服 Evacetrapib(LY2484595)(30 毫克/千克)8 小时后,高密度脂蛋白胆固醇(HDL-C)增加了 129.7%。在两项剂量反应研究中,计算得出 Evacetrapib (LY2484595) 口服 8 小时后 CETP 抑制活性的 ED50 值分别为 3.5 mg/kg 和 4.1 mg/kg。Evacetrapib(LY2484595)(< 200 mg/kg)不会增加扎克糖尿病脂肪大鼠的血压。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 胆固醇酯转移蛋白抑制剂 |
产品介绍 |
Evacetrapib (LY2484595)是高活性CETP选择性抑制剂,IC50为5.5 nM,能在不增加醛固酮和血压的情况下提高高密度脂蛋白胆固醇。 Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. |
ALogP | 7.7 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
分子类型 | 小分子 |
---|---|
IUPAC Name | 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylic acid |
INCHI | InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1 |
InChi Key | IHIUGIVXARLYHP-UXNJHFGPSA-N |
Canonical SMILES | CC1=CC(=C2C(=C1)C(CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C |
Isomeric SMILES | CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C |
PubChem CID | 49836058 |
分子量 | 638.65 |
溶解性 | DMSO 12.8 mg/mL Water <1 mg/mL Ethanol 12.8 mg/mL |
---|---|
分子量 | 638.600 g/mol |
XLogP3 | 7.700 |
氢键供体数Hydrogen Bond Donor Count | 1 |
氢键受体数Hydrogen Bond Acceptor Count | 13 |
可旋转键计数Rotatable Bond Count | 7 |
精确质量Exact Mass | 638.28 Da |
单同位素质量Monoisotopic Mass | 638.28 Da |
拓扑极表面积Topological Polar Surface Area | 87.400 Ų |
重原子数Heavy Atom Count | 45 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 973.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Purity(HPLC) | 98-100(%) |
---|---|
Appearance(E128064) | Light yellow to yellow solid |
NMR spectrum | Conforms to Structure |
1. Fernandez MC, Escribano A, Mateo AI, Parthasarathy S, Martin de la Nava EM, Wang X, Cockerham SL, Beyer TP, Schmidt RJ, Cao G et al.. (2012) Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.. Bioorg Med Chem Lett, 22 (9): (3056-62). [PMID:22497761] [10.1021/op500134e] |
2. Rader DJ, deGoma EM. (2014) Future of cholesteryl ester transfer protein inhibitors.. Annu Rev Med, 65 (13): (385-403). [PMID:24422575] [10.1021/op500134e] |
3. Sahebkar A, Chew GT, Watts GF. (2014) Recent advances in pharmacotherapy for hypertriglyceridemia.. Prog Lipid Res, 56 (13): (47-66). [PMID:25083925] [10.1021/op500134e] |
4. Ready JM. (2021) Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP).. J Med Chem, 64 (18): (13212-13214). [PMID:34498872] [10.1021/op500134e] |